Literature DB >> 24414392

Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies.

Hong Wang1, Li Ren, Yifeng He, Ye Wei, Zenggan Chen, Weige Yang, Yipeng Fu, Xiaoyue Xu, Weigao Fu, Guangfu Hu, Wenhui Lou.   

Abstract

Previous epidemiological studies have evaluated the association between common variations of cytochrome P450 (CYP)2C9 (430C>T and 1075A>C) and the risk of colorectal cancer (CRC) with conflicting results. To derive a more precise estimation of the relationship between these CYP2C9 polymorphisms and CRC, a meta-analysis was performed. PubMed, Embase, CNKI, and Web of Science databases were searched. A total of 16 studies including 9,463 cases and 11,416 controls were identified. Potential sources of heterogeneity including ethnicity, sample size of study, genotyping method, diagnostic criteria, and outcome were systematically assessed. Overall, the summary odds ratio of 430T variant for CRC was 0.92 (95% confidence interval (CI) 0.86-0.98; P = 0.012) and 1.39 (95% CI 1.07-1.81; P = 0.013) for colorectal adenomas (CRAs). As for CYP2C9 1075A>C polymorphism, no significant results were observed in overall and subgroup analysis. There was no evidence of publication bias. In conclusion, there is evidence to indicate a significant association between CYP2C9 430C>T polymorphism and CRC/CRA risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24414392     DOI: 10.1007/s13277-013-1566-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

Review 2.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

Authors:  F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

Review 3.  Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility.

Authors:  Edyta Reszka; Wojciech Wasowicz; Jolanta Gromadzinska
Journal:  Br J Nutr       Date:  2006-10       Impact factor: 3.718

Review 4.  Energy intake, overweight, physical exercise and colorectal cancer risk.

Authors:  A Giacosa; S Franceschi; C La Vecchia; A Favero; R Andreatta
Journal:  Eur J Cancer Prev       Date:  1999-12       Impact factor: 2.497

5.  Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.

Authors:  C Martínez; E García-Martín; J M Ladero; J Sastre; F Garcia-Gamito; M Diaz-Rubio; J A Agúndez
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.

Authors:  Louise E McGreavey; Faye Turner; Gillian Smith; Katherine Boylan; D Timothy Bishop; David Forman; C Roland Wolf; Jennifer H Barrett
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

Review 8.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

Review 9.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  4 in total

1.  Age-Specific Regulation of Drug-Processing Genes in Mouse Liver by Ligands of Xenobiotic-Sensing Transcription Factors.

Authors:  Cindy Yanfei Li; Helen J Renaud; Curtis D Klaassen; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2015-11-17       Impact factor: 3.922

2.  Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study.

Authors:  Jolantha Beyerle; Andreana N Holowatyj; Mariam Haffa; Eva Frei; Biljana Gigic; Petra Schrotz-King; Juergen Boehm; Nina Habermann; Marie Stiborova; Dominique Scherer; Torsten Kölsch; Stephanie Skender; Nikolaus Becker; Esther Herpel; Martin Schneider; Alexis Ulrich; Peter Schirmacher; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister; Ulrike Haug; Robert W Owen; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

3.  Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.

Authors:  Harsh Sheth; Emma Northwood; Cornelia M Ulrich; Dominique Scherer; Faye Elliott; Jennifer H Barrett; David Forman; C Roland Wolf; Gillian Smith; Michael S Jackson; Mauro Santibanez-Koref; Robert Haile; Graham Casey; Mark Jenkins; Aung Ko Win; John L Hopper; Loic Le Marchand; Noralane M Lindor; Stephen N Thibodeau; John D Potter; John Burn; D Timothy Bishop
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

4.  The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.

Authors:  Xiangkun Wang; Tingdong Yu; Xiwen Liao; Chengkun Yang; Chuangye Han; Guangzhi Zhu; Ketuan Huang; Long Yu; Wei Qin; Hao Su; Xiaoguang Liu; Tao Peng
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.